{"disease":{"id":"nasopharyngeal-neoplasms","name":"nasopharyngeal neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00342147","title":"Family Study of Head and Neck Cancers in Taiwan","phase":"","overall_status":"COMPLETED","enrollment_count":3795,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01257100","title":"Environmental and Genetic Determinants of NPC","phase":"","overall_status":"TERMINATED","enrollment_count":3500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00393224","title":"Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families","phase":"","overall_status":"TERMINATED","enrollment_count":952,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03942380","title":"Cell-free Tumor DNA in Head and Neck Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Christian von Buchwald","has_results":false},{"nct_id":"NCT07326358","title":"AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03840421","title":"GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":468,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03837808","title":"Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":384,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01528618","title":"Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":362,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02611960","title":"Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06811844","title":"Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05544929","title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04870905","title":"Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","has_results":false},{"nct_id":"NCT05807880","title":"Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":59,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06019130","title":"Nivolumab in Children and Adults With Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":57,"lead_sponsor_name":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","has_results":false},{"nct_id":"NCT04446663","title":"Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"First People's Hospital of Foshan","has_results":false},{"nct_id":"NCT02269943","title":"Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT06688175","title":"IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":32,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT03854838","title":"IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07277764","title":"Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":23,"lead_sponsor_name":"Jiangxi Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT03180476","title":"Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Sichuan Cancer Hospital and Research Institute","has_results":false},{"nct_id":"NCT03769467","title":"Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Atara Biotherapeutics","has_results":true}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}